FDA Approves Crizotinib for Children and YA Patients with R/R ALCL

On January 14, 2021, the U.S. Food and Drug Administration (FDA) approved crizotinib for pediatric patients 1 year of age and older and young adults (YA) with relapsed or refractory (R/R), systemic anaplastic large cell lymphoma (ALCL)  that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive  ALCL.

Read the FDA announcement.

Read Pfizer's announcement.

Posted 1/15/2021

FDA Approves Osimertinib for the Adjuvant Treatment of EGFRm NSCLC

Durvalumab Dosing Update

Durvalumab (Imfinzi^®, AstraZeneca) has been approved in the U.S. for an additional dosing option for patients with a body weight of 30 kg and more: 1500 mg administered intravenously every four weeks in the approved indication of unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy. Patients with body weight <30 kg must receive weight-based dosing, equivalent to IMFINZI 10 mg/kg every 2 weeks.

Read the press release.

Posted on 12/15/2020. 

FDA Approves Additional Indication for Pembrolizumab

Pembrolizumab (Keytruda^®, Merck) has received FDA approval, in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express programmed death ligand 1 (PD-L1) [combined positive score (CPS ≥10)] as determined by an FDA-approved test. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Select patients for treatment with KEYTRUDA in combination with chemotherapy based on the presence of positive PD-L1 expression in:
- locally recurrent unresectable or metastatic TNBC

Read prescribing information and Medication Guide.

Posted on 12/07/2020

Pfizer + BioNTech Announce EUA Request to FDA for COVID-19 Vaccine

Registration Open: Review of Efficacy and Safety of Monjuvi® (tafasitamab-cxix)

Monjuvi^® (tafasitamab-cxix, Incyte) in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Join a one-hour webcast, Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix): FDA-approved monoclonal antibody in combination with lenalidomide for adult patients with R/R DLBCL who have received at least one prior therapy, to learn more about the usage of Monjuvi®, (tafasitamab-cxix) in treating your patients. 

Wednesday, December 16
1:00 - 2:00 PM EST

Presented by:
Moshe Levy, MD
Director of Hematologic Malignancies Research; Hematology Associate
Texas Oncology, PA; Baylor University College of Medicine

REGISTER

Wednesday, December 16
3:00 - 4:00 PM EST

Presented by:
John M. Pagel, MD, PhD
Chief of Hematologic Malignancies and Director of Stem Cell Transplantation
Swedish Cancer Institute

REGISTER

FDA Approves Pembrolizumab + Chemotherapy for TNBC

Registration Open: Jakafi (ruxolitinib) Product Theater

Intervening With Jakafi^® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion 

Jakafi^® (ruxolitinib) is indicated for the treatment of patients with polycythemia vera who have had an inadequate response to—or are intolerant of—hydroxyurea; patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF; and for the  treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

Join a one-hour live presentation—sponsored by Incyte Corporation—to learn more about the use of Jakafi^® (ruxolitinib) in treating your patients. 

Monday, November 30
12:00 - 1:00 PM EST

Presented by:
Solomon Hamburg, MD, PhD
Clinical Professor of Medicine, Division of Hematology-Oncology, Department of Medicine
UCLA Beverly Hills Hematology Oncology
REGISTER

Monday, November 30
3:00 - 4:00 PM EST

Presented by:
Jonathan Abbas, MD
Director, Acute Leukemia Program
Tennessee Oncology
REGISTER

FDA Approves Expanded Indication of Pembrolizumab for R/R cHL

Webcast for Lynparza PAOLA-1 Launch

Join professionals from across the country for an expert discussion on Lynparza (olaparib, AstraZeneca), and Lynparza + bevacizumab as maintenance monotherapy or combination therapy in advanced ovarian cancer: results from key clinical trials.

Important Notes

• Members will be directed to a registration site which will give them the option to choose from all 6 webcasts

• Members will be required to input their information to register for an event

• Members can add the event to their calendar from the registration site or the registration confirmation email

• Members will receive a reminder email 1 day and 30 minutes prior to the webcast

Details and registration.